WO2005063224A1 - Preparations topiques contenant du dimethylsulfoxyde et du dexpanthenol - Google Patents

Preparations topiques contenant du dimethylsulfoxyde et du dexpanthenol Download PDF

Info

Publication number
WO2005063224A1
WO2005063224A1 PCT/EP2004/014620 EP2004014620W WO2005063224A1 WO 2005063224 A1 WO2005063224 A1 WO 2005063224A1 EP 2004014620 W EP2004014620 W EP 2004014620W WO 2005063224 A1 WO2005063224 A1 WO 2005063224A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
dexpanthenol
preparations according
contain
dmso
Prior art date
Application number
PCT/EP2004/014620
Other languages
German (de)
English (en)
Inventor
Peter Rose
Bernd Ibscher
Peter Schneider
Ruland Fridrich
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of WO2005063224A1 publication Critical patent/WO2005063224A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to a pharmaceutical topical preparation for the treatment of various indications, containing dimethyl sulfoxide, hereinafter also called DMSO, and dexpanthenol.
  • DMSO is a polar, odorless liquid, for which a variety of physical and therapeutic effects or functions are known. Et al These are radioprotective and cryoprotective effects, as well as membrane penetration, loosening of scar tissue, anti-inflammatory effects and radical trapping.
  • DMSO has been used for around 25 years as a topical medication for the treatment of blunt traumas and diseases from the rheumatic range, as well as a carrier in various antiviral and antifungal preparations.
  • Doloben® gel in an amount of 15% by weight in combination with heparin or Rheumabene® in an amount of 10% by weight.
  • Dexpanthenol is a pantothenic acid derivative which, according to WO 93/21899, is used as an active ingredient in an anti-acne agent, the agent being able to contain DMSO as a penetration aid.
  • DE 196 20 341 describes a geriatricum which can contain dexpanthenol as a absorption mediator and, if appropriate, DMSO to improve percutaneous absorption. According to WO 03/011247, dexpanthenol is also used as a skin penetration enhancer.
  • EP 0 380 989 describes a plaster for transdermal use which contains dexpanthenol in a concentration of 0.1 to 50% by weight as a penetration aid.
  • the object of the present invention is to provide a pharmaceutical topical preparation with a high content of dimethyl sulfoxide and good skin tolerance.
  • the above-mentioned object was achieved by the provision of a pharmaceutical topical preparation which contains 10-60% by weight of dimethyl sulfoxide and 2-15% by weight of dexpanthenol together with conventional auxiliaries and excipients.
  • the weight data are based on the total weight of the preparation.
  • Figure 1 is a graphical representation of transepidermal water loss (TEWL) when using preparations containing DMSO and dexpanthenol.
  • Dexpanthenol the alcohol of pantothenic acid (vitamin B6), is quickly converted into the effective pantothenic acid after dermal absorption in the body. Dexpanthenol has been shown to reduce skin irritation when applied externally and has previously been used primarily for cosmetic applications.
  • a third tolerance study then examined the occurrence of skin irritation depending on the ratio of DMSO and dexpanthenol.
  • the transepidermal water loss (TEWL) determined in a placebo-controlled, double-blind study can be regarded as a sign of tolerance. The higher the transepidermal water loss in the patient at the application site, the less the tolerance of the preparation can be considered.
  • 20 healthy volunteers were given gel preparations containing 10% by weight dexpanthenol and 20, 40 and 60% by weight DMSO. The transepidermal water loss was then measured after 3, 24, 48, 72 and 96 hours. The preparations with dexpanthenol showed a significantly lower water loss than preparations without dexpanthenol.
  • the maximum TEWL for the gel base was 7.2 g / h * m 2 (after 96 hours).
  • the TEWL values of the preparation with 20% by weight DMSO were only slightly higher (max. 10.45 g / h * m 2 after 72 hours) than with the placebo preparation. The results are summarized in Table 1 and shown graphically in FIG. 1.
  • preparations with 20% DMSO in combination with 10% dexpanthenol are particularly advantageous in terms of increased tolerance. It can also be seen that even preparations with 60% DMSO are well tolerated. Furthermore, the preparations can be modified to lower DMSO contents in such a way that the DMSO / dexpanthenol ratio remains approximately constant. For these preparations according to the invention, for example preparations of 20% DMSO with 3.33% dexpanthenol, there is therefore a very particular superiority with regard to good tolerability combined with increased effectiveness.
  • the preparations according to the invention contain DMSO as the active ingredient. In general, they contain no other active ingredient. If desired, the preparations can also contain further active ingredients, for example anti-inflammatory or anti-rheumatic active ingredients, anticoagulants, fibrinolytic active ingredients, etc.
  • Preferred preparations contain 3 to 15% by weight and in particular 3 to 10% by weight of dexpanthenol.
  • Preferred embodiments of the preparations according to the invention contain:
  • the quantitative ratio (w / w) of DMSO to dexpanthenol is preferably in the range from 10: 1 to 2: 1, in particular 6: 1 to 4: 1.
  • the preparations according to the invention can be in the form of a gel, spray, emulgel, ointment, cream, solution or lotion and can contain customary auxiliaries which are suitable for the preparation of these use forms.
  • the preparations are preferably in the form of a gel.
  • the gels are in particular hydrophilic and generally contain 0.2 to 40% by weight, in particular 0.2 to 10% by weight and particularly preferably 0.2 to 5% by weight, of gel-forming substances.
  • Suitable gel-forming substances are organic gel formers, for example polyacrylic acids, cellulose derivatives, such as hydroxyalkyl celluloses, for example hydroxyethyl cellulose or hydroxypropyl cellulose, methyl cellulose or carboxymethyl cellulose, alginic acid derivatives, polyglycols, such as polyethylene glycol or polypropylene glycol, etc., or inorganic gel formers, for example bentonite silica, for example bentonite silicate , Hydroxyethyl cellulose, hydroxypropyl cellulose and in particular polyacrylic acid are preferred.
  • organic gel formers for example polyacrylic acids, cellulose derivatives, such as hydroxyalkyl celluloses, for example hydroxyethyl cellulose or hydroxypropyl cellulose, methyl cellulose or carboxymethyl cellulose, alginic acid derivatives, polyglycols, such as polyethylene glycol or polypropylene glycol, etc.
  • inorganic gel formers for example bentonite si
  • the gels can contain solvents such as water-miscible alcohols, for example ethanol, isopropanol, ethylene glycol, propylene glycol etc.
  • the gels can also contain humectants, such as glycerin, propylene glycol, sorbitol, polyethylene glycols, polyoxyethylene glycol esters, such as polyoxyethylene glycol trihydroxystearate (macrogol glycerol hydroxystearate) or laurate, polyoxyethylene sorbitan monooleate (polysorbate 80) etc.
  • the preparations according to the invention are useful for the treatment of blunt traumas and diseases of the rheumatic type, inflammation and pain of the musculoskeletal system as well as venous leg disorders and acute neuralgia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des préparations topiques pharmaceutiques contenant 10 à 60 % en poids de diméthylsulfoxyde et 2 à 15 % en poids de dexpanthénol. Ces préparations présentent une bonne tolérance cutanée.
PCT/EP2004/014620 2003-12-23 2004-12-22 Preparations topiques contenant du dimethylsulfoxyde et du dexpanthenol WO2005063224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361022A DE10361022A1 (de) 2003-12-23 2003-12-23 Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
DE10361022.7 2003-12-23

Publications (1)

Publication Number Publication Date
WO2005063224A1 true WO2005063224A1 (fr) 2005-07-14

Family

ID=34706540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014620 WO2005063224A1 (fr) 2003-12-23 2004-12-22 Preparations topiques contenant du dimethylsulfoxyde et du dexpanthenol

Country Status (2)

Country Link
DE (1) DE10361022A1 (fr)
WO (1) WO2005063224A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062746A3 (fr) * 2007-11-17 2009-08-13 Bayer Consumer Care Ag Médicaments topiques pour le traitement antimycotique
WO2010125470A3 (fr) * 2009-04-28 2011-06-16 Foamix Ltd. Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
RU2550916C1 (ru) * 2013-12-26 2015-05-20 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция для лечения заболеваний опорно-двигательного аппарата
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
WO2016133471A1 (fr) 2015-02-20 2016-08-25 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. Composition topique contenant de la mupirocine et du dexpanthénol
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11612560B2 (en) * 2015-09-08 2023-03-28 The University Of Toledo Treatment of Raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (TRPM-8)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
DE19610396A1 (de) * 1996-03-16 1997-09-18 Krewel Meuselbach Gmbh Dimethylsulfoxid-haltige topische Zubereitung
US20030199644A1 (en) * 2002-04-12 2003-10-23 Kim Young So Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
DE20319986U1 (de) * 2003-12-23 2004-04-15 Merckle Gmbh Chemisch Pharmazeutische Fabrik Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3902013A1 (de) * 1989-01-25 1990-09-20 Knoll Ag Pflaster zur transdermalen anwendung
EP0639068A1 (fr) * 1992-05-05 1995-02-22 The Procter & Gamble Company Composition de traitement de l'acne
DE19620341A1 (de) * 1996-05-21 1997-11-27 Erich Dr Med Dr Phil Both Geriatrin (Medikament gegen Altersbeschwerden in percutaner Einreibung)
DE10136784A1 (de) * 2001-07-27 2003-02-20 Lohmann Therapie Syst Lts Darreichungsformen mit wirkstoffhaltigen Partikeln, zur Anwendung auf der Haut oder Schleimhaut

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
DE19610396A1 (de) * 1996-03-16 1997-09-18 Krewel Meuselbach Gmbh Dimethylsulfoxid-haltige topische Zubereitung
US20030199644A1 (en) * 2002-04-12 2003-10-23 Kim Young So Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
DE20319986U1 (de) * 2003-12-23 2004-04-15 Merckle Gmbh Chemisch Pharmazeutische Fabrik Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRO KATHRIN ET AL: "Efficacy of dexpanthenol in skin protection against irritation: A double-blind, placebo-controlled study.", CONTACT DERMATITIS, vol. 49, no. 2, August 2003 (2003-08-01), pages 80 - 84, XP002326600, ISSN: 0105-1873 *
BUNDESVERBAND DER PHARMAZEUTISCHEN INDUSTRIE E.V. (BPI) ET AL.: "Rote Liste 2002", 2002, EDITIO CANTOR VERLAG, AULENDORF, XP002326601 *

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009062746A3 (fr) * 2007-11-17 2009-08-13 Bayer Consumer Care Ag Médicaments topiques pour le traitement antimycotique
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2010125470A3 (fr) * 2009-04-28 2011-06-16 Foamix Ltd. Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
RU2550916C1 (ru) * 2013-12-26 2015-05-20 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция для лечения заболеваний опорно-двигательного аппарата
WO2016133471A1 (fr) 2015-02-20 2016-08-25 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. Composition topique contenant de la mupirocine et du dexpanthénol
US11612560B2 (en) * 2015-09-08 2023-03-28 The University Of Toledo Treatment of Raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (TRPM-8)
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
DE10361022A1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
WO2005063224A1 (fr) Preparations topiques contenant du dimethylsulfoxyde et du dexpanthenol
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
DE3119017C2 (fr)
DE60018881T2 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
KR950008305B1 (ko) 2상 용매 담체 조성물
DE3032462A1 (de) Praeparate zur anwendung an oder in geweben und/oder fluessigkeiten des menschlichen oder tierischen koerpers
EP0773022B3 (fr) Composition pharmaceutique pour le traitement de la rhinite, contenant un sympathomimétique et du pantothenol et/ou de l'acide pantothénique
DE69027220T2 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE60112431T2 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
EP1532986B1 (fr) Composition pharmaceutique pour le traitement de la rhinite
DE1804801C3 (de) Mittel zur Aknebehandlung
DE69634472T2 (de) Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung
DE19541919C2 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
EP0285856A2 (fr) Emploi de dihydroergotamine et de ses sels pour le traitement local de troubles trophiques
EP1196159B1 (fr) Utilisation de tosylchloramide(s) pour le traitement de maladies de la peau, de la muqueuse, d'organes et de tissus
EP0450123B1 (fr) Composition pharmaceutique pour application topique contenant du diclofenac-sodium
DE20319986U1 (de) Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
WO2006122668A1 (fr) Combinaisons de matieres actives formees de glycerides de glucosyle et de creatine et/ou de creatinine
EP2822537B1 (fr) Agent de polytherapie pour le traitement de rhinites
EP1507524B1 (fr) Utilisation topicale de diuretiques pour traiter les oedemes
WO2002069927A1 (fr) Preparations de melatonine-vitamine-a
WO1996012504A1 (fr) Formulation du type 'huile dans l'eau' pour application locale
EP0442063B1 (fr) Emploi du 2',4',6'-triméthoxy-4-(1-pyrrolidinyl) butyrophénone dans le traitement topique de maladies trophiques
DE3741415C1 (en) Use of 5-[N-(3,4-dimethoxyphenylethyl)-N-methylamino]-2-(3,4-dimethoxyphenyl) -2-isopropylvaleronitril ("verapamil") or its pharmaceutically suitable salts for the percutaneous treatment of chronic venous insufficiency
WO2004035055A1 (fr) Utilisation d'agonistes de recepteur de dopamine pour traiter des tumeurs cutanees, des verrues et des cicatrices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase